Starling Oncology Inc.
NASDAQ · STLNFormed in 2007, the business of what is now The Oncology Institute, Inc. ("TOI", the "Company", "we", or "our) and its affiliated professional corporations was created initially as a collection of community oncology practices in southern California, and has evolved to be a national leader in the pursuit of reducing the ever-rising cost of oncology care, while embracing clinical best practices, state-of-the-art technology, and compassionate treatment of patients. While we continue our original purpose of seeing our patients on a fee-for-service basis for their oncology, hematology, specialty infusion, oral pharmacy needs, as well as enrolling patients in clinical trials, where appropriate, TOI's true mission lies in our differentiated ability to partner with managed care providers and other risk-bearing entities to transfer the risk and patient coordination responsibility of treating cancer in the subset of the population that is experiencing an oncology treatment episode. To do this, we utilize a combination of gain/loss sharing, capitation, and full delegation contracts at the population-level, which allow TOI to control the treatment of oncology patients in an outpatient setting,
From the 10-K filed Mar 12, 2026
as of Oct 22, 2026 · today 6.53, 75% of the way from low to high
No dividends on record.
A company that pays none, or whose history has not arrived yet, shows nothing here.
Valuation
Results, trailing twelve months
Balance and cash
Shares and market
Financial statements
Total operating revenue +27.8% $393.41M → $502.73M, year ended Dec 31, 2025
Comps
Valuation, growth and margins against the closest competitors
Filings
10-K filed Mar 12, 2026 · 10-Q Aug 6, 2026
| Filing | Filed |
|---|---|
| 10-Q for Quarter Ended June 2026 | Aug 6, 2026 |
| 10-Q for Quarter Ended March 2026 | May 7, 2026 |
| 10-K for Fiscal Year Ended December 2025 | Mar 12, 2026 |
| 10-Q for Quarter Ended September 2025 | Nov 13, 2025 |
Insiders
$23.51M sold $2.69M bought · open market, 12 months to Aug 21, 2026
| Insider | Type | Value |
|---|---|---|
| Brad HivelyAug 21, 2026 | Sale | $1.95M ↗ |
| Jorey ChernettAug 14, 2026 | Purchase | $78.48K ↗ |
| Jorey ChernettJul 21, 2026 | Purchase | $94.86K ↗ |
| Yale PodnosJul 14, 2026 | Sale | $34.79K ↗ |
Funds (13F)
39.6% held by 122 managers · as of Sep 30, 2026
| Manager | Value | Change |
|---|---|---|
| BlackRock, Inc. | $25.79M | +333.16K (+7.5%) |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $18.25M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $17.73M | −211.25K (−6.1%) |
| JOSH ARNOLD INVESTMENT CONSULTANT, LLC | $13.38M | — |
| GEODE CAPITAL MANAGEMENT, LLC | $10.32M | +142.15K (+8.1%) |
Congress
12 trades 12 sales · 0 purchases · 1 members, 12 months
| Member | Type | Amount |
|---|---|---|
| Richard BlumenthalSep 23, 2026 | Partial sale | $1K–$15K |
| Richard BlumenthalSep 23, 2026 | Partial sale | $1K–$15K |
| Richard BlumenthalSep 22, 2026 | Partial sale | $1K–$15K |
| Richard BlumenthalSep 22, 2026 | Partial sale | $15K–$50K |
Short interest
7.35% of float · 5.62 days to cover · Oct 15, 2026
Short position, last two years · 71% of its 2-year range
Source: FINRA
In the press
No headlines in the business press in the last 30 days.
Company data reported to the SEC on EDGAR (CIK 1799191).
Member research
Everything on STLN, in full
Every fiscal year and quarter as filed, the filing reader with highlights and AI summaries, insider and fund activity, congressional trades, short interest history, earnings calls, the full price history and every peer. A 7-day free trial, then a subscription.